Mucosal approaches to HIV vaccine development

The route of inoculation determines the tissue tropism of modified vaccinia Tiantan expressing the spike glycoprotein of SARS-CoV in mice

The live replication‐competent modified vaccinia virus Tiantan (MVTT) is an attractive vaccine vector, yet little is known about its tissue tropism and pathology in vivo. Recently, we demonstrated that a recombinant MVTT expressing the spike glycoprotein of SARS‐CoV (namely MVTT‐S) is superior to the non‐replicating modified vaccinia Ankara (MVA‐S) for inducing high level of neutralizing antibodies through mucosal vaccination. In this study, we further determined the tissue tropism and safety of MVTT‐S after the vaccine was administrated through various routes including: intramuscular (i.m.), intranasal (i.n.), and intravaginal (i.vag.) inoculations, respectively. Using real‐time PCR, nested PCR, immunohistochemistry and in situ hybridization assays, we found that MVTT‐S was able to produce a transient infection in all cases within 48 hr post‐inoculation, yet the major site of viral replication in various tissues or organs was dependent on the route of viral administration. We demonstrated that i.m. injection of MVTT‐S primarily targeted draining inguinal lymph nodes, whereas mucosal inoculation had broader range of tissue infections. i.n. inoculation involved infections in lungs, kidneys, spleens and cervix lymph nodes while i.vag. administration targeted uteruses, ovaries, kidneys and spleens. Critically, the infection did not cause severe pathogenic consequences in infected tissues, which was consistent to the attenuated phenotype of MVTT‐S. Our findings have implications for the optimization of vaccination route and for studies on the correlation between the magnitude of immune responses and the extent of tissue involvement in vivo. J. Med. Virol. 82: 727–734, 2010. © 2010 Wiley‐Liss, Inc.

Attitudes about human immunodeficiency virus immunization: the influence of health beliefs and vaccine characteristics

BACKGROUND AND OBJECTIVES

The development of a vaccine to prevent human immunodeficiency virus (HIV) infection is a highly desirable goal. However, there may be a number of psychosocial barriers to HIV vaccine acceptance. The purpose of this study was to begin to examine some factors that might influence attitudes about HIV immunization.

GOAL

To evaluate the relationship of health beliefs and vaccine characteristics to acceptability of hypothetical HIV immunization.

STUDY DESIGN

The subjects were 222 college students who completed self-administered questionnaires that addressed health beliefs, vaccine characteristics, and acceptability of hypothetical HIV vaccines.

RESULTS

Health beliefs independently predictive of HIV vaccine acceptability included perceived susceptibility to HIV, perceived nonmembership in a traditionally defined acquired immune deficiency syndrome (AIDS) risk group, and fear of the vaccine causing AIDS. Of the vaccine characteristics, efficacy influenced vaccine acceptability most strongly, followed by type of vaccine.

CONCLUSION

These results suggest that universal HIV vaccine acceptance cannot be assumed and that vaccine characteristics and individuals' health beliefs are likely to influence decisions regarding HIV immunization.

Microsporidium-Associated Sinusitis

Two cases of biopsy-proven Microsporidium-associated chronic sinusitis in HIV-seropositive patients are presented. Spores of Septata intestinalis were identified by light microscopy and confirmed by electron microscopy in each case. Both patients displayed severe deficiencies of nasal mucosa CD4-positive cells, demonstrated by immunohistochemical methods. Only two other cases of Septata intestinalis-associated sinusitis have been reported previously. Our observations agree with the theory that functional defects in local mucosal immunity may partially explain the acquisition of opportunistic mucosal infections in many HIV-seropositive patients.

Salivary binding antibodies induced by human immunodeficiency virus type 1 recombinant gp120 vaccine. The NIAID AIDS Vaccine Evaluation Group

Salivary binding antibodies induced by candidate human immunodeficiency virus type 1 (HIV-1) vaccines in healthy, HIV-1 uninfected volunteers were assessed in a clinical trial evaluating intramuscularly injected HIV-1MN recombinant gp120 (rgp120) vaccine alone or with HIV-1IIIB rgp120 vaccine. The two rgp120 vaccines induced envelope glycoprotein-specific immunoglobulin G (IgG) and IgA antibodies in whole saliva and serum.

Immunobiological aspects of HIV treatment

Recent information on the efficacy of anti-retroviral therapy and vaccination strategies has been disappointing as well as confusing. The recently announced Concorde study suggested that there is no advantage to early treatment of asymptomatic HIV infection with azidothymidine alone, even though the levels of CD4+ cells in the treated group were consistently higher than in the untreated group. This will lead to increasing attention being paid to the mechanisms whereby HIV causes AIDS, which have sadly been sidelined in the rush to produce classically based therapies and vaccines. Over the last year many different theories on how HIV kills CD4+ cells and leads to AIDS have been discussed and tentatively explored.